p38α regulates actin cytoskeleton and cytokinesis in hepatocytes during development and aging

Ana M. Tormos1, Sergio Rius-Pérez1, María Jorques1, Patricia Rada2,3, Lorena Ramírez4, Ángela M. Valverde2,3, Ángel R. Nebreda4,5, Juan Sastre1, Raquel Taléns-Visconti6*

1 Department of Physiology, University of Valencia. Burjassot, Valencia, Spain, 2 Instituto de Investigaciones Biomédicas Alberto Sols (Centro Mixto CSIC-UAM), Arturo Dupuyer 4, Madrid, Spain, 3 Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem), ISCIII, Madrid, Spain, 4 Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain, 5 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, 6 Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia. Burjassot, Valencia, Spain

☯ These authors contributed equally to this work.
* raquel.talens@uv.es

Abstract

Background

Hepatocyte polyploidization is an age-dependent process, being cytokinesis failure the main mechanism of polyploid hepatocyte formation. Our aim was to study the role of p38α MAPK in the regulation of actin cytoskeleton and cytokinesis in hepatocytes during development and aging.

Methods

Wild type and p38α liver-specific knock out mice at different ages (after weaning, adults and old) were used.

Results

We show that p38α MAPK deficiency induces actin disassembly upon aging and also cytokinesis failure leading to enhanced binucleation. Although the steady state levels of cyclin D1 in wild type and p38α knock out old livers remained unaffected, cyclin B1- a marker for G2/M transition- was significantly overexpressed in p38α knock out mice. Our findings suggest that hepatocytes do enter into S phase but they do not complete cell division upon p38α deficiency leading to cytokinesis failure and binucleation. Moreover, old liver-specific p38α MAPK knock out mice exhibited reduced F-actin polymerization and a dramatic loss of actin cytoskeleton. This was associated with abnormal hyperactivation of RhoA and Cdc42 GTPases. Long-term p38α deficiency drives to inactivation of HSP27, which seems to account for the impairment in actin cytoskeleton as Hsp27-silencing decreased the number and length of actin filaments in isolated hepatocytes.
Conclusions

p38α MAPK is essential for actin dynamics with age in hepatocytes.

Introduction

Polyploid cells contain more than two complete sets of chromosomes and they are very common in liver tissue [1–3]. Hepatocyte poliploidization is considered an age dependent-process that occurs mainly during liver development and postnatal maturation. However, poliploidization changes can take place also in adult liver as a result of increasing age or cellular stresses such as surgical resection, toxic exposure or viral infections [3]. In any case, the poliploidization process generates tetraploid or octoploid hepatocytes with one (mononucleated hepatocytes) or two nuclei (binucleated hepatocytes) [2, 3]. Although several mechanisms of polyploid cell formation have been reported in mammals, including endoreduplication, endomitosis and mitotic slippage, incomplete cytokinesis is the main mechanism of polyploid hepatocyte formation in the liver [1–4]. Physiological failure of cytokinesis in the liver occurs after the end of the suckling (weaning), associated with insulin signaling via the phosphatidylinositol 3 kinase—protein kinase B (PI3K-AKT) pathway [5] and increases progressively with age [6, 7]. Therefore, most hepatocytes are diploid in young individuals, while more than half are polyploid in adults [8].

The cleavage of the mother cell into two daughter cells during cytokinesis, the last step of cell division, implies re-organization of the actin cytoskeleton to assembly the myosin and actin contractile ring that allows the formation of the cleavage furrow [9–14]. Formation of the cleavage furrow is a critical structure for successful cytokinesis execution and must be regulated properly to ensure that chromosomes and organelles are distributed equally to each daughter cell [15]. Filamentous actin (F-actin) together with additional structural and regulatory proteins plays an important role in the cleavage furrow formation. Localized activation of the small GTPases Ras homolog (Rho) family, including RhoA, Cdc42 and Rac1 are essential for furrow formation in animal cells promoting actin polymerization and stimulating myosin activity [16–19]. Insufficient activation of this pathway could perturb proper initiation of cytokinesis and could induce cytokinesis failure. On the other hand, the role of coflin in actin depolymerization to maintain actin dynamics is essential for cytokinesis completion [18, 19].

Cytokinesis failure results in the formation of genetically unstable polyploid cells so understanding the mechanisms of cytokinesis is a central problem in cell biology with potential relevance in tumorigenesis [12]. Paradoxically, during postnatal development of the liver, polyploid hepatocytes may be generated physiologically as a result of failures either in the cytoskeleton reorganization or in activation of molecular signals essential for hepatocyte cleavage [3].

The binucleation ratio of the liver seems to be directly connected with the proliferative capacity of hepatocytes. During postnatal liver growth, when poliploidization is established, hepatocytes exhibit lower ability to proliferate. This occurs because many hepatocytes manage to finish karyokinesis, but most of them fail to complete cytokinesis thus generating binuclear cells [2, 3]. Interestingly, hepatocytes are able to change from polyploid to diploid, and from binucleated to mononucleated during organism’s life by a phenomenon called somatic ‘reductive mitoses’, thanks to multipolar mitotic spindles [20]. In fact, ploidy reversal is a useful tool to enhance hepatocyte proliferation, which is especially beneficial after liver hepatecotomy when a rapid liver tissue growth is required [3] [21].

We have already observed that binucleation reversal after biliary cirrhosis was reduced upon p38α deficiency showing the key role of p38α in hepatocyte proliferation [22]. The p38α MAPK regulates cytokinesis.
MAPK family consists of 4 members: p38α, p38β, p38γ (SAPK, stress-activated protein kinase) 3, and p38δ (SAPK4) [23], being p38α ubiquitously expressed at high levels in most cell types [24]. p38 MAPKs are activated by environmental and genotoxic stress and play key roles in the control of cell proliferation, differentiation and survival, as well as in the regulation of the inflammatory response [25],[22]. In fact, p38 MAPKs participate in inflammatory diseases such as rheumatoid arthritis [26], Crohn’s disease [27], asthma [28] and chronic obstructive pulmonary disease [29], as well as in other pathological conditions like cardiovascular diseases [30, 31], cancer [32, 33], or pain [34, 35]. Accordingly, p38 MAPK inhibitors have demonstrated adequate properties to treat inflammatory diseases and other conditions. Several p38 MAPK inhibitors, most of which have reached phase 2 clinical studies, have been developed [36, 37] [38–42]. However, many of them have been discontinued due to adverse effects such as gastrointestinal disorders, liver anomalies and ALT elevations, among others [35] [40, 41].

Regarding the regulation of hepatocyte proliferation by p38α, it is known that p38α regulates the G1/S and G2/M cell-cycle checkpoints prior to DNA synthesis and cell division, respectively [43–45]. So far increased proliferation and impaired differentiation have been considered hallmarks of p38α-deficient cells [46]. Thus, mice with liver-specific deletion of p38α exhibited enhanced hepatocyte proliferation after partial hepatectomy [47] and developed more liver tumors with increased number of proliferative tumor cells [48]. Accordingly, activation of p38 MAPK resulted in hepatocyte growth arrest and inhibition of DNA synthesis in cultured fetal rat hepatocytes [43]. In addition, inhibition of p38 MAPK in vivo is sufficient to trigger a marked increase in the number of proliferating hepatocytes [43]. Nevertheless, paradoxically we recently found that liver-specific p38α deficiency lowered hepatocyte proliferation and enhanced hepatocyte binucleation in biliary cirrhosis [22], which suggested that p38α might influence the last step of mitosis. Therefore, in the present manuscript we have explored in more depth the role of p38α in the regulation of cytokinesis progression and actin cytoskeleton in hepatocytes during development and aging.

Materials and methods

Animals

p38α was specifically down-regulated in the hepatocytes by using mice carrying p38α floxed alleles1 and the Afp-Cre transgene that expresses Cre under the control of the α-fetoprotein promoter, which is active during embryonic hepatic development. The liver-specific p38α knock out (KO) mice were kept in a C57BL/6 genetic background [49]. We performed experiments with wild type and p38α knock out mice at three different ages: after weaning (4 weeks-old), adults (10–12 weeks-old) and old (18–24 months-old). Four to six animals were used for each experimental group.

All mice were cared for in accordance with the criteria outlined in the Guide for the Care and Use of Laboratory Animals (NIH publication 86–23 revised 1985) and they were cared under controlled conditions of temperature (23±1°C), relative humidity (50–60%) and light/dark cycles (12h/12h) with food and water ad libitum. Mice were anesthetized with isoflurane 3–5% and once they were unconscious they were exsanguinated. Death was confirmed by cervical dislocation. The study was approved by the Ethics Committee of Animal Experimentation and Welfare of the University of Valencia (Valencia, Spain).

Primary hepatocyte cell culture

Primary mouse hepatocytes were isolated from non-fasting male C57BL/6 mice (3–4 months) by a two-step collagenase perfusion as previously described [50]. Briefly, cells were seeded on collagen-coated 12-well plate (Corning, Inc.) and cultured at density of 350,000 cells/well in 1
ml medium containing Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium (1:1) supplemented with 10% FBS, 2 mM glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 1 mM sodium pyruvate (attachment medium) and maintained under a humidity conditions in 95% air and 5% CO₂ at 37°C for 24 h before siRNA transfection. For cell staining experiments, collaged-coated coverslips were used.

**Genes knockdown by siRNA**

Cells were transfected with 25 nM siRNAs or with a scrambled siRNA, used as control, following DharmaFECT General Transfection Protocol (Dharmacon) to knock down mouse p38α and Hsp27 expression. Cells were used 48 h later for experiments. DharmaFECT siRNA Transfection Reagent, p38α siRNA (SMARTpool: ON-TARGETplus Mapk14 siRNA L-040125-00-0005 5 nmol), Hsp27 siRNA (SMARTpool: ON-TARGETplus Mouse Hspb1 siRNA L-045651-00-0005 5 nmol) and scramble siRNA were obtained from Dharmacon.

**Western blotting**

For total liver homogenates, protein was extracted with Heidolph (RZR 2021) homogenizer in Hepes lysis buffer pH 7.4 with 1mM DTT, 1mM sodium orthovanadate, 50mM sodium fluoride, 30mM sodium pyrophosphate, 1% Igepal, 10% glycerol and protease inhibitor cocktail (Sigma Aldrich). To obtain total cell lysates, attached cells were scraped off and incubated for 10 min on ice with lysis buffer. Homogenates and cell lysates were centrifuged during 15 min at 15000 rpm, 4°C. In case of nuclei isolation, a slight modification of the nuclei isolation method described by [51] was used. Chemiluminescence was detected with a charge-coupled device camera (Biorad Chemidoc XRS+ Molecular Imager and LAS-3000, Fujifilm) using the ECL system (Luminata Classico, Millipore). Antibodies used were as follows: AKT (Genscript A00301); α tubulin (Sigma Aldrich T6074); cyclin B1 (sc-245), cyclin D1 (sc-20044), GSK3β (sc-9166), HSP27 (sc-5962), MK2 (sc-7871), p21 (sc-6246), p38 alpha (sc-535), p-GSK3β (BS4084) from Santa Cruz Biotechnology; tata binding protein (abcam, 818); MNK1 (Novus biological, H00008569-M14); p-AKT (Ser473) (4058), β catenin (9562), p-cofilin (Ser 3) (3131), cofilin (5175), p-HSP27 (Ser82)(2401), p-H3 (Ser10) (4511XP), p-MKK1 (Thr197/202) (2111), p27 (2552), from Cell Signaling Technology. Secondary antibodies were from Jackson Immunoresearch: Donkey anti rabbit (711-035-152), donkey anti mouse (715-035-151) and donkey anti goat (715-035-151).

**F-actin polymerization assay**

Frozen livers were used for this assay, as no differences were found between fresh and frozen livers. This technique was performed as indicated by manufacturer (BK003 Cytoskeleton). Briefly, after stabilizing actin using the buffer provided by the manufacturer, the liver tissue was homogenized and the proteins extracted as described above. The lysate was centrifuged at 350 g for 5 minutes at room temperature. Then, the supernatant was centrifuged at 100,000 g, 1 h at 37°C to obtain F-actin/G-actin fractions which were quantified by Western blotting.

**GTPase activity measurement for RhoA, Cdc42, Rac1**

The measurement was performed as described by the manufacturer (BK036, BK034, and BK035 respectively). Frozen livers were homogenized and total lysates were centrifuged at 10000g, 1min, 4°C, as preclearing. Once bead titration was accomplished, immunoprecipitation was performed with 15uL of beads and 1mg/mL of liver lysate in the case of Rhotekin.
RBD beads and 10μL of beads and 0.5mg/mL of liver lysate in the case of PAK-PBD beads. All of them required 1mL final volume.

Immunohistochemistry and cell staining
Formalin-fixed, paraffin embedded sections of liver tissue were deparaffinised using HistoClear® (National Diagnostics). As an alternative for xylene and antigen retrieval, tissue sections were autoclaved in citrate buffer pH 6 for β-catenin staining or digested with proteinase K in TE buffer at 37°C, in the case of filamentous actin (F-actin). Slides were blocked with 5% BSA in PBS. Antibodies used in immunofluorescence were β-catenin (Cell Signaling Technology, 9562) and F-actin (Acris antibodies, SM1349P). Nuclei were stained with DAPI (Life Technologies, D1306). For binucleation rate (percentage of binucleated cells/ total number of cells) and number of nuclei per field, 50–60 slides from all different animals were blindly scored.

For in vitro assays, primary hepatocytes seeded on collagen-coated glass coverslips (10 mm) in 12-well plates were fixed with 4% paraformaldehyde for 6 min, washed with PBS and permeabilised with 0.1% Triton X-100 during 5 min. Actin was detected by incubating cells for 1 h with Texas Red®-X phalloidin (ThermoFisher) and nuclei were stained with DAPI. An OLYMPUS FV1000MPE confocal microscope was used for image acquisition.

TUNEL assay
Formalin-fixed, paraffin embedded sections were deparaffinised using xylene and then, antigen retrieval was performed by citrate buffer (37°C, 15 minutes). Nucleotide labelling and detection were performed as described following manufacturer’s instructions (In Situ Cell Death Detection Kit 11 684 817 910, Roche).

Statistical analysis
Results are given as mean ± standard deviation (s.d.). Significant differences were assessed by one-way analysis of variance (ANOVA) followed by a Tukey’s post-hoc test. Differences were considered statistically significant at p<0.05.

Results
Binucleation rises in hepatocytes from liver-specific p38α knock out mice
In order to explore the role of p38α in the regulation of cytokinesis in hepatocytes during development and aging, we have determined the binucleation rate by immunohistochemistry in the three groups of mice analysed after weaning, in adult, and in old stages. We have found that p38α deficiency enhanced hepatocyte binucleation at all stages when compared with their corresponding wild type counterparts. The highest binucleation rate (>50%) was found in old p38α knock out mice. Strikingly, the binucleation rate rose with age in both wild type and p38α knock out mice (Fig 1A).

In addition, the liver mass ratio (liver weight/ mouse weight x 100) was determined at different ages of wild type and liver-specific p38α knock out mice, and we found that p38α deficiency reduced liver mass in old mice (Fig 1B). Indeed, although no differences were detected liver mass between after weaning and adult mice, there was a significant decrease in the liver mass of old p38α knock out mice compared with old wild type mice.

To have an estimation of hepatocyte size, the number of hepatocytes per field was determined and it was not affected by p38α deficiency. Therefore, a decline in hepatocyte size
MAPK regulates cytokinesis

A

WT

p38α KO

binucleation rate

hepatocytes per field

%

0

10

20

30

40

50

60

70

80

after weaning

adult

old

WT

KO

WT

p38α KO

B

liver ratio (%)

% 0

2

4

6

after weaning

adult

old

WT

KO

WT

KO

WT

KO

C

After weaning

Adult

Old

WT

KO

WT

KO

WT

KO

WT

KO
should not account for the reduction in liver mass observed in old p38α knock-out animals (Fig 1A).

Hepatocytes from p38α knock out mice actively enter into mitosis but fail to complete cytokinesis

In order to assess whether impaired hepatocyte proliferation due to cell cycle blockade could explain the reduced liver mass upon p38α deficiency and aging, phosphorylated histone 3 (p-H3), cyclin B1 and cyclin D1 were measured in the liver as indexes of proliferative status and potential mitotic delay or blockade. The proliferative rate was markedly increased in livers from both groups only after weaning based on p-H3 levels (Fig 1C). In addition, no significant differences were found in p38α phosphorylation levels upon aging. We decided to focus on old animals because they exhibited major differences in binucleation rates and liver mass. Although the steady state levels of cyclin D1 in wild type and p38α knock out old livers were similar, cyclin B1 was significantly overexpressed in p38α knock out mice (Fig 2A).

On the other hand, the reduced liver mass upon p38α deficiency and aging should not be ascribed to apoptosis, which was not increased upon p38 deficiency. Indeed, cleaved PARP and TUNEL positive hepatocytes were not increased in liver from old p38α knock out mice (Fig 2B and 2C).

p38α is essential for actin polymerization in hepatocytes upon aging

To investigate the possible mechanism underlying the cytokinesis impairment that occurs upon p38α deficiency in the liver, we studied the actin cytoskeleton by immunohistochemistry in livers from wild type and liver-specific p38α knock out mice at all ages. Although after weaning no differences were found, some abnormalities in the cytosolic distribution of actin filaments in adult mice upon p38α deficiency were observed (Fig 3A). A severe impairment in the F-actin filamentous structure was found in the liver from old p38α knock out mice (Fig 3A), as evidenced by dramatic loss of actin cytoskeleton. Furthermore, F-actin polymerization was assessed by separation of F-actin and G-actin fractions, and F-actin was markedly decreased in old p38α knock out mice leading to an increase in G-actin/F-actin ratio in these old mice (Fig 3B).

Long-term p38α deficiency triggers hyper-activation of RhoA and Cdc42 GTPases

The Ras homolog (Rho) family plays a central role in organizing the actin cytoskeleton and in the regulation of cytokinesis [16, 17]. Therefore the GTPase activity of the three major components of Rho GTPases—the Ras homolog A (RhoA), Ras-related C3 botulinum toxin substrate 1 (Rac1), and Cdc42—were measured in the liver of old mice both wild type and p38α knock out. Surprisingly, the activities of RhoA and Cdc42 GTPases increased in old p38α knock out mice in comparison with old wild type mice. No significant changes were found in Rac1 activity (Fig 4A).
Long-term p38α deficiency increases p21 levels and activates nuclear coflin

RhoA activity may be inhibited by p27 [52], and additionally the RhoA downstream pathway may be blocked by p21 or coflin [53, 54]. Hence, p27 and p21 levels as well as the activation of...

![Diagram A: Nuclear extract from old wild type and p38α knockout liver were Western blotted for cyclin B1 and cyclin D1. Tata binding protein was used as a loading control and densitometric quantification of cyclin D1/TBP and cyclin B1/TBP was performed.](image)

![Diagram B: Apoptosis in wild type and p38α knockout old liver sections was measured by the number of positive nuclei using TUNEL (Scale bars = 100 μm). Apoptotic ratio was calculated as: TUNEL positive nuclei/total nuclei.](image)

![Diagram C: Old wild type and p38α knockout livers were Western blotted for PARP and cleaved PARP and densitometric quantification of PARP cleavage (cleaved PARP/PARP) was performed. Data are shown as mean and SD. *P < 0.05 WT versus KO.](image)
cofilin by phosphorylation were assessed. Nuclear levels of phosphorylated cofilin, but not cytosolic levels, increased upon p38α deficiency in old mice (Fig 4B and 4C). Cytosolic p27 levels did not change significantly, whereas p21 levels increased in the liver of p38α knock out mice (Fig 4B).

p38α drives activation of MNK1 in old mice

MAPK-interacting Ser/Thr kinase 1 (MNK1) and MAPK-activated protein kinase 2 (MK2) are major downstream targets of the p38α pathway that have been implicated in the regulation
A

Old WT  Old p38α KO

RhoA pull down  RhoA total

Active RhoA/RhoA

WT  p38α KO

Active Cdc42/Cdc42

WT  p38α KO

Active Rac1/Rac1

WT  p38α KO

B

Cytosolic fraction

Old WT  Old p38α KO

p-cofilin  coflin  α tubulin

p-cofilin(S3)/cofilin (cytosolic fraction)

WT  p38α KO

p27/α tubulin  p21/α tubulin

p27  p21

WT  p38α KO

C

Nuclear fraction

Old WT  Old p38α KO

p-cofilin  coflin  Tata binding protein

p-cofilin (S3)/cofilin (nuclear fraction)

WT  p38α KO
of cytokinesis and actin dynamics [55–57]. Hence their activation was studied in the liver of old wild type and p38α knockout mice as the major changes in cytokinesis and actin cytoskeleton were found in these mice. MNK1 is activated by phosphorylation and is required for abscission of the intercellular bridge at the end of cytokinesis [55]. MNK1 phosphorylation was markedly diminished by p38α deficiency in the liver of old mice (Fig 5B). Hence, MNK1 down-regulation may be involved in the cytokinesis failure that occurs in the liver of these mice.

Strikingly, MK2 phosphorylation on threonine 334 was completely abrogated in the liver from p38α knock out mice, but its phosphorylation on threonine 222 was not affected. However, phospho-AKT (Ser473) and phospho-glycogen synthase kinase 3 beta (GSK3β (Ser9)) did not show significant changes in liver of old p38 knockout old mice (Fig 5B). Thus, AKT activity is not affected by MK2 inactivation and hence, it seems that the AKT pathway is not related to the impairment of the actin cytoskeleton in these mice.

Long-term p38α deficiency drives to Hsp27-dependent loss of actin polymerization

Heat shock protein 27 (HSP27) is another downstream target of p38α than can be also activated by MK2 and regulates the stability of actin filaments [58]. Phosphorylation of HSP27 was strongly diminished in old p38α knockout mice (Fig 5B), in which the most dramatic F-actin disassembly was found.

In order to confirm the role of p38α and HSP27 in actin polymerization, these targets were silenced by siRNA in primary cultures of hepatocytes (Fig 6B). Hsp27 silencing decreases the number and length of actin filaments in hepatocytes whereas no changes were found when p38α MAPK was silenced (Fig 6A). Strikingly, phosphorylation levels of HSP27 remained unchanged in p38α-silenced hepatocytes (Fig 6C). Accordingly, we measured phosphorylation levels of HSP27 in the liver of WT and p38α knockout mice at all ages. Interestingly, the decrease in HSP27 phosphorylation was specific for the long-term p38α deficiency, as it was only found in old mice but not after weaning or adult mice (Fig 7).

Discussion

Polyploidy accompanies late fetal development and postnatal maturation of hepatocytes [4, 5], reaches a plateau at maturity, and increases later on with aging [1]. This is a physiological feature of the liver and the increase in polyploidy that occurs with age is to a great extent independent of p38α. Nevertheless, in our model, in each group of age studied, the binucleation rate increases in p38α knock out mice compared with their corresponding wild type counterparts, especially upon aging. The lack of p38α leads to decreased liver mass in old mice without apparent changes in hepatocyte size. Moreover, the TUNEL staining and the cleaved PARP/PARP ratio remained unaffected upon p38α-deficiency in old mice showing that the reduced liver mass observed in our model should not be ascribed to apoptosis. Therefore, we
hypothesized that inactivation of p38α should impair hepatocyte proliferation by affecting cell division in old mice.

It is known that p38α regulates the G1/S and G2/M cell cycle checkpoints prior to DNA synthesis and cell division, respectively [43–45, 59]. Accordingly, we have analyzed these checkpoints of the cell cycle. Livers from p38α knock out old mice showed up-regulation of cyclin B1, but they did not exhibit cyclin D1 overexpression. Cyclin D1 is a marker of the G1/S transition, whereas cyclin B1 is a marker for G2/M transition [59]. Hence, increased B1 levels suggest that hepatocytes from p38α knock out mice enter more actively into mitosis. In fact, increased proliferation have been considered hallmark of p38α-deficient cells [46] and mice with liver-specific deletion of p38α exhibited enhanced hepatocyte proliferation [47] and developed

Fig 5. p38α-mediated phosphorylation pathways. a. Old wild type and p38α knock out livers were Western blotted for phosphorylated MKK3/6 and MKK4, for phosphorylated p38 and total levels of p38α. Densitometric quantification of p-MKK3/6 (S189/207)/α-tubulin, p-MKK4 (S257/T261)/α tubulin were done. b. Old wild type and p38α knock out livers were Western blotted for MNK1 and phosphorylated MNK1 on Thr197/202, for MK2 and phosphorylated MK2 on Thr334 and Thr222, for AKT and phosphorylated AKT on Ser473, for GSK3β and phosphorylated GSK3β on serine 9 and for HSP27 and phosphorylated HSP27 on Ser 82. α-tubulin was used as a loading control. Densitometric quantification of p-MNK1(T197/202)/MNK1, p-MK2 (T334)/MK2, p-MK2 (T222)/MK2, p-AKT(S473)/AKT, p-GSK3β(S9)/GSK3β and p-HSP27(S82)/HSP27 were determined. Data are shown as mean ± SD. **P < 0.01 WT versus KO.

doi:10.1371/journal.pone.0171738.g005
Fig 6. Actin polymerization in isolated hepatocytes. 

**p38α MAPK-silenced and Hsp27-silenced.**

**a.** Representative image of actin filaments staining by phalloidin (red) and DAPI (blue) in isolated hepatocytes treated with scramble, p38α MAPK siRNA and Hsp27 siRNA (Scale bars = 1000 μm).

**b.** Silencing of p38α MAPK and Hsp27 targets by siRNA in isolated hepatocytes.

**c.** Isolated hepatocytes scramble-treated and p38α MAPK siRNA-treated were Western blotted for p-p38 (Thr180/Tyr182), p38α, p-HSP27 (Ser82) and HSP27.

doi:10.1371/journal.pone.0171738.g006
more liver tumors [48]. However, the highest binucleation rate observed in our model would suggest that although hepatocytes from p38α knockout mice enter actively into mitosis, fail to complete cell division, particularly cytokinesis. Interestingly, although incomplete cytokinesis is a common phenomenon in hepatocytes explaining the presence of hepatic polyploidy in the liver [1], under certain circumstances polyploidy is considered a protumoral feature that may give rise to cancer [60].

It is known that the increase in ploidy rate and cytokinesis failure that occurs after weaning was associated with activation of the AKT pathway [5]. Indeed, primary hepatocytes cultured with PI3K and AKT inhibitors reduced these failed cytokinetic events [61]. The activation of RhoA at the division site induced by AKT inhibition allowed proper cytoskeleton reorganization [62], and thus, successful cytokinetic performance was achieved [61]. In fact, it has been reported that although the PI3K-AKT pathway is required for G2/M progression, its inactivation is necessary for mitotic exit [63]. In addition, AKT downstream targets such as mammalian target of rapamycin complex 2 (mTORC2) and GSK3β have been described as cytoskeleton

Fig 7. Only the in vivo animal model with a long-term p38α deficiency drives to inactivation of HSP27. Wild type and p38α knockout livers of all groups of age were Western blotted for p-HSP27 (Ser82) and total HSP27. α-tubulin was used as a loading control. Data are shown as mean ± SD. * P < 0.05 WT versus KO; $ $ P < 0.01 old versus adult.

doi:10.1371/journal.pone.0171738.g007
regulators [56, 57, 64]. However, the p38α-dependent hepatic ploidy should not be ascribed to stimulation of the AKT pathway because it remained unaffected. Hepatocyte binucleation triggered by p38α-deficiency at all ages could be ascribed to reduced activation of MNK1, which should affect the final step of cytokinesis, i.e. abscission of the intercellular bridge. Indeed, MNK1 is activated by phosphorylation directly triggered by p38 MAPK [65] and it is required for localization of centrin to the midbody and subsequent abscission [55]. Accordingly, its silencing induced the formation of multinucleated cells due to cytokinesis failure [55]. Hence, our results suggest that MNK1 is a critical target of p38α whose inactivation would lead to binucleated cells at all ages, but especially upon aging.

During cytokinesis, actin dynamics play a critical role in animal cells [12]. At the end of mitosis, the actin network rearranges at the cleavage furrow and composes the contractile ring, which is essential in the process of cytokinesis [13]. Our results show that the long-term absence of p38α severely impairs actin cytoskeleton leading to a high presence of binucleated hepatocytes. The abnormalities in F-actin polymerization start in adult p38α knock out hepatocytes, and become severe in old p38α knock out mice. In fact, in these animals the G-actin/F-actin ratio was significantly increased. Thus, the severity of damage in actin cytoskeleton in p38α knock out old mice could explain the higher differences in the binucleation rate in comparison with wild type animals upon aging. In young animals, the effect of p38α deletion in actin cytoskeleton is more moderate and could not explain the differences observed in the ploidy in this group of age. The main mechanism that explains how the impairment of the actin cytoskeleton can drive to blockage of cytokinesis execution is related to the cleavage furrow formation [66]. The exact structure of the cleavage furrow remains unclear but several studies have shown how F-actin is required to interact with myosin and other scaffolding proteins such as septins and anillin during furrow formation [66, 67]. Moreover, cytokinesis completion depends on actin dynamics in the furrow as well as on the preexisting actin filaments that are nucleated outside the cleavage site [66]. Hence, when stimulation of actin filament assembly fails and actin dynamics is impaired, blockage of cytokinesis takes place.

Rho family GTPases are essential regulators of actin dynamics during the cell cycle, especially during cytokinesis [13, 16] organizing the assembly of the contractile ring and triggering the actomyosin-driven constriction of the cleavage furrow [12, 18, 67]. In fact, significant deficiencies in F-actin polymerization could also be due to inactivation of the RhoA pathway [17]. Rac1 and Cdc42 GTPases may also regulate the assembly or disassembly of filamentous F-actin and importantly may activate p38 through p21-activated kinase 1 (PAK1) [13]. p38α MAPK also acts as a downstream target of the Rho family, and particularly of its three major members RhoA, Rac1, and Cdc42 via mixed lineage kinases (MLKs) [68] (Fig 8). Thus, p38 activation is likely to contribute to the biological effects of Rac and Cdc42 on actin cytoskeleton, affecting cell growth and proliferation, and regulating feedback loops [66].

Our findings show that long-term p38α deficiency triggers abnormal hyperactivation of both RhoA and Cdc42 GTPases, which is likely to be caused by p38α-dependent blockade of their downstream pathways. Indeed, RhoA activity triggers proteasome-mediated degradation of p21, which directly inhibits RhoA kinase (ROCK) [53] (Fig 8). However, p21 levels markedly increased upon long-term p38α deficiency, which should cause downstream down-regulation of the RhoA pathway. It has been reported that F-actin disruption stabilizes and enhances p21 levels [53] and this could explain the observed increase in p21 levels. In any case, the absence of net p21 degradation indicates that the RhoA pathway is blocked downstream at certain step because it is unable to trigger p21 degradation. On the other hand, hyperactivation of Cdc42 and dual specificity mitogen-activated protein kinase kinase 3/6 (MKK3/6) when p38α is absent would indicate the existence of a positive feedback loop that induces upstream the pathway Cdc42-PAK1-MKK3/6 that normally would lead to p38 activation [69] (Fig 8).
Moreover, the hyperactivity of Cdc42 might interfere with cytokinesis since Cdc42 inhibition is considered necessary for cytokinesis completion [70, 71].

In regard to cofilin, increased phosphorylation in the nucleus would inhibit the actin-depolymerizing activity of nuclear cofilin in old p38α knock out mice [72], thus protecting F-actin
polymerization in the nucleus where it is implicated in several nucleus processes related with transcription and gene expression regulation specially during cell cycle [73–77] (Fig 8).

The dramatic loss of actin cytoskeleton in the cytosol associated with severely impaired actin polymerization upon aging could be ascribed to decreased phosphorylation of HSP27. HSP27 is a highly conserved oligomeric protein that has a critical function in the equilibrium between polymerization and depolymerization of actin filaments [58]. HSP27 displays actin-capping activity that is inhibited by phosphorylation [78], and thus phosphorylation of HSP27 markedly modifies this equilibrium in favor of polymerized actin, contributing to the maintenance of the microfilament network and to formation of the cleavage furrow [58] (Fig 8). In hepatocarcinoma cells, p38-mediated activation of HSP27 promotes migration and invasion because of the promotion of actin remodeling [79, 80]. Accordingly, activation of p38 MAPK in cells exposed to cytochalasin D increased the stability of the actin microfilaments in a HSP27 phosphorylation-dependent manner [58]. RhoA/Rho kinase pathway can promote p38α-mediated HSP27 phosphorylation in rabbit facial vein [81], and in in osteoblasts [81–83]. The association between HSP27 and RhoA was already described in muscle cells [84, 85] modulating actin-myosin interaction [86]. Nevertheless, in CCI39 cells p38 phosphorylation and HSP27 phosphorylation occurred independently of the Rho pathway [58]. Our results suggest that upon aging p38α induces HSP27 phosphorylation in order to keep the appropriate F-actin network for successful cytokinesis, whereas p38α deficiency enhances binucleation with age. MK2 may mediate p38α-dependent HSP27 phosphorylation [87–89] (Fig 8). MK2 activation depends on phosphorylation of the activation loop (Thr222) and the regulatory domain (Thr334), being the latter required for migration of the p38-MK2 complex from the nucleus to the cytoplasm [90]. As the lack of p38α in liver leads to absence of MK2 phosphorylation on Thr334 and to an age-dependent decrease of HSP27 phosphorylation, alteration of actin cytoskeleton would be expected. p-38 independent redundant mechanisms involved in HSP27 phosphorylation should maintain its normal levels in young and adult mice, but these redundant mechanisms would fail in the liver of old animals. Accordingly, silencing of Hsp27 in hepatocytes abrogated the actin microfilament network but neither Hsp27 phosphorylation nor actin cytoskeleton, were affected when p38α was silenced. This result could be explained because we have employed a transient p38 silencing method. In fact, only the in vivo animal model with a long-term p38α deficiency drives to inactivation of HSP27 thus disturbing cytoskeleton dynamics.

In conclusion, long-term p38α deficiency severely impairs actin cytoskeleton inducing actin disassembly and cytokinesis failure by reducing both HSP27 phosphorylation and MNK1 phosphorylation in the liver of old animals. Thus, p38α is essential to maintain in actin dynamics with age in hepatocytes. In addition, long-term p38α deficiency triggered RhoA and Cdc42 hyperactivation, but increased p21 levels that may inhibit downstream the RhoA pathway. The dramatic loss of actin cytoskeleton observed upon p38α deficiency with age should be taken into account when using p38 inhibitors for chronic therapies in the clinical practice.

Author contributions

**Conceptualization:** RTV JS.

**Data curation:** AMT SRP.

**Formal analysis:** AMT.

**Funding acquisition:** JS RTV AMV ARN.

**Investigation:** AMT SRP MJ PR LR.
Methodology: AMT RTV JS.

Project administration: RTV JS.

Resources: RTV JS ARN.

Supervision: RTV JS AMV.

Validation: RTV.

Visualization: AMT RTV JS.

Writing – original draft: AMT SRP RTV JS.

Writing – review & editing: AMT SRP RTV JS ARN.

References

1. Gentic G, Desdouets C, Celton-Morizur S. Hepatocytes polyploidization and cell cycle control in liver physiopathology. Int J Hepatol. 2012; 2012:282430. Epub 2012/11/15. doi: 10.1155/2012/282430 PMID: 23150829

2. Gentic G, Celton-Morizur S, Desdouets C. Polyploidy and liver proliferation. Clin Res Hepatol Gastroenterol. 2012; 36(1):29–34. Epub 2011/07/23. doi: 10.1016/j.clinre.2011.05.011 PMID: 21778131

3. Gentic G, Desdouets C. Polyploidization in liver tissue. Am J Pathol. 2014; 184(2):322–31. Epub 2013/10/22. doi: 10.1016/j.amjpath.2013.06.035 PMID: 24140012

4. Margall-Ducos G, Celton-Morizur S, Couton D, Bregere O, Desdouets C. Liver tetraploidization is controlled by a new process of incomplete cytokinesis. J Cell Sci. 2007; 120(Pt 20):3633–9. Epub 2007/09/27. doi: 10.1242/jcs.016907 PMID: 17895361

5. Celton-Morizur S, Merlen G, Couton D, Margall-Ducos G, Desdouets C. The insulin/Akt pathway controls a specific cell division program that leads to generation of binucleated tetraploid liver cells in rodents. J Clin Invest. 2009; 119(7):1880–7. Epub 2009/07/16. doi: 10.1172/JCI38677 PMID: 19603546

6. Gupta S. Hepatic polyploidy and liver growth control. Semin Cancer Biol. 2000; 10(3):161–71. Epub 2000/08/11. doi: 10.1006/scbi.2000.0317 PMID: 10936066

7. Nunez F, Chipchase MD, Clarke AR, Melton DW. Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21. FASEB J. 2000; 14(9):1073–82. Epub 2000/06/02. PMID: 10834928

8. Duncan AW. Aneploidy, polyploidy and ploidy reversal in the liver. Semin Cell Dev Biol. 2013; 24(4):347–56. Epub 2013/01/22. doi: 10.1016/j.semcdb.2013.01.003 PMID: 23337933

9. Glotzer M. Animal cell cytokinesis. Annu Rev Cell Dev Biol. 2001; 17:351–86. Epub 2001/11/01. doi: 10.1146/annurev.cellbio.17.1.351 PMID: 11687493

10. Zeitlin SG, Sullivan KF. Animal cytokinesis: breaking up is hard to do. Curr Biol. 2001; 11(13):R514–6. Epub 2001/07/27. PMID: 11470423

11. Guertin DA, Trautmann S, McCollum D. Cytokinesis in eukaryotes. Microbiol Mol Biol Rev. 2002; 66(2):155–78. Epub 2002/06/01. doi: 10.1128/MMBR.66.2.155-178.2002 PMID: 12040122

12. Barr FA, Gruneberg U. Cytokinesis: placing and making the final cut. Cell. 2007; 131(5):847–60. Epub 2007/11/30. doi: 10.1016/j.cell.2007.11.011 PMID: 18045532

13. HengYW, KohCG. Actin cytoskeleton dynamics and the cell division cycle. Int J Biochem Cell Biol. 2010; 42(10):1622–33. Epub 2010/04/24. doi: 10.1016/j.biocel.2010.04.007 PMID: 20412688

14. Schiel JA, Prekeris R. Making the final cut—mechanisms mediating the abscission step of cytokinesis. ScientificWorldJournal. 2010; 2010:1424–34. Epub 2010/07/28. doi: 10.1100/tsw.2010.129 PMID: 20661535

15. D’Avino PP, Savoian MS, Glover DM. Cleavage furrow formation and ingression during animal cytokinesis: a microtubule legacy. J Cell Sci. 2005; 118(Pt 8):1549–58. Epub 2005/04/07. doi: 10.1242/jcs.02335 PMID: 15811947

16. Pickny A, Werner M, Glotzer M. Cytokinesis: welcome to the Rh zone. Trends Cell Biol. 2005; 15(12):651–8. Epub 2005/10/26. doi: 10.1016/j.tcb.2005.10.006 PMID: 16243528

17. Sit ST, Manser E. Rho GTPases and their role in organizing the actin cytoskeleton. J Cell Sci. 2011; 124(Pt 5):679–83. Epub 2011/02/16. doi: 10.1242/jcs.064964 PMID: 21321325
18. Normand G, King RW. Understanding cytokines is failure. Adv Exp Med Biol. 2010; 676:27–55. Epub 2010/08/07. PMID: 20687468

19. Sumi T, Matsumoto K, Takai Y, Nakamura T. Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42-activated LIM-kinase 2. J Cell Biol. 1999; 147(7):1519–32. Epub 1999/12/30. PMID: 10613909

20. Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, Olson SB, et al. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature. 467(7316):707–10. Epub 2010/09/24. doi: 10.1038/nature09414 PMID: 20861837

21. Mossin L, Blankson H, Huitfeldt H, Seglen PO. Ploidy-dependent growth and binucleation in cultured rat hepatocytes. Exp Cell Res. 1994; 214(2):551–60. Epub 1994/10/01. doi: 10.1006/excr.1994.1293 PMID: 7925649

22. Tormos AM, Arduini A, Talens-Visconti R, del Barco Barrantes I, Nebreda AR, Sastre J. Liver-specific p38alpha deficiency causes reduced cell growth and cytokinesis failure during chronic biliary cirrhosis in mice. Hepatology. 2013; 57(5):1950–61. Epub 2013/01/29. doi: 10.1002/hep.26174 PMID: 23354775

23. Danese A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010; 429(3):403–17. Epub 2010/07/16. doi: 10.1042/BJ20100323 PMID: 20626350

24. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007; 1773(8):1358–75. Epub 2007/05/08. doi: 10.1016/j.bbamcr.2007.03.010 PMID: 17481747

25. Campbell JS, Argast GM, Yuen SY, Hayes B, Fausto N. Inactivation of p38 MAPK during liver regeneration. Int J Biochem Cell Biol. 2011; 43(2):180–8. Epub 2010/08/17. doi: 10.1016/j.biocel.2010.08.002 PMID: 20708092

26. Corb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum. 2006; 54(9):2745–56. Epub 2006/09/02. doi: 10.1002/art.22080 PMID: 16947383

27. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006; 12(30):4807–12. Epub 2006/08/29. doi: 10.3748/wjg.v12.i30.4807 PMID: 16937461

28. Pongratz G, McAlees JW, Conrad DH, Erbe RS, Haas KM, Sanders VM. The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK- and CD23-dependent manner. J Immunol. 2006; 177(5):2926–38. Epub 2006/08/22. PMID: 16920928

29. Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D. Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J. 2013; 42(1):28–41. Epub 2012/10/13. doi: 10.1183/09031936.00170711 PMID: 23060629

30. Martin ED, Bassi R, Marber MS. p38 MAPK in cardioprotection—are we there yet? Br J Pharmacol. 2015; 172(8):2101–13. Epub 2014/09/11. doi: 10.1111/bph.12901 PMID: 25204838

31. Fisk M, Gajendragadkar PR, Maki-Petaja KM, Wilkinson IB, Cheriyann J. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Am J Cardiovasc Drugs. 2014; 14(3):155–65. Epub 2014/02/08. doi: 10.1007/s40256-014-0063-6 PMID: 24504769

32. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer. 2003; 97(12):3017–26. Epub 2003/06/05. doi: 10.1002/cncr.11425 PMID: 12784337

33. Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, et al. Inhibition of p38 alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X (L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia. 2006; 20(6):1017–27. Epub 2006/04/18. doi: 10.1038/sj.leu.2404200 PMID: 16617327

34. Svensson CI, Schafers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett. 2005; 379(3):209–13. Epub 2005/04/22. doi: 10.1016/j.sj.leu.2004.12.064 PMID: 15843065

35. Xu JT, Xin WJ, Wei XH, Wu CY, Ge YX, Liu YL, et al. p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp Neurol. 2007; 204(1):355–65. Epub 2007/03/30. doi: 10.1016/j.expneurol.2006.11.016 PMID: 17258708

36. Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther. 2008; 327(3):610–9. Epub 2008/09/09. doi: 10.1124/jpet.108.139006 PMID: 18776065

37. Duffy JP, Harrington EM, Salturro FG, Cochran JE, Green J, Gao H, et al. The Discovery of VX-745: A Novel and Selective p38alpha Kinase Inhibitor. ACS Med Chem Lett. 2011; 2(10):758–63. Epub 2011/10/13. doi: 10.1021/ml2001455 PMID: 24900264
38. Damjanov N, Kauffman RS, Spencer-Greene GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009; 60(5):1232–41. Epub 2009/05/01. doi: 10.1002/art.24485 PMID: 19404957

39. Tong SE, Daniels SE, Black P, Chang S, Prother A, Desjardins PJ. Novel p38alpha mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain. J Clin Pharmacol. 2012; 52(5):717–28. Epub 2011/06/11. doi: 10.1177/0091270011405496 PMID: 21659629

40. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011; 38(5):846–54. Epub 2011/02/03. doi: 10.3899/jrheum.100602 PMID: 21285160

41. Schreiber S, Feagan B, D’Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006; 4(3):325–34. Epub 2006/03/11. doi: 10.1016/j.cgh.2005.11.013 PMID: 16527696

42. Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomized phase 2 trial. Lancet. 2014; 384(9949):1187–95. Epub 2014/06/17. doi: 10.1016/S0140-6736(14)60417-7 PMID: 24930728

43. Awad MM, Enslen H, Boylan JM, Davis RJ, Gruppuso PA. Growth regulation via p38 mitogen-activated protein kinase in developing liver. J Biol Chem. 2000; 275(49):38716–21. Epub 2000/09/21. doi: 10.1074/jbc.M00840200 PMID: 10995779

44. Ambrosino C, Nebreda AR. Cell cycle regulation by p38 MAP kinases. Biol Cell. 2001; 93(1–2):47–51. Epub 2001/12/04. PMID: 11730321

45. Thornton TM, Rincón M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 2009; 5(1):47–51. Epub 2009/01/23. PMID: 19159010

46. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009; 9(8):537–49. Epub 2009/07/25. doi: 10.1038/nrc2694 PMID: 19629069

47. Hui L, Bakiri L, Stepienak E, Wagner EF. p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle. 2007; 6(20):2429–33. Epub 2007/10/25. doi: 10.4161/cc.6.20.4774 PMID: 17957136

48. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 2007; 39(6):741–9. Epub 2007/05/01. doi: 10.1038/ng2033 PMID: 17468757

49. Ventura JJ, Tenbaum S, Perdiguer o E, Huth M, Guerra C, Barbacid M, et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet. 2007; 39(6):750–8. Epub 2007/05/01. doi: 10.1038/ng2037 PMID: 17468755

50. Benveniste R, Danoff TM, Ilekis J, Craig HR. Epidermal growth factor receptors in male and female mouse primary hepatocyte cultures. Cell Biochem Funct. 1988; 6(4):231–5. Epub 1988/10/01. doi: 10.1002/cbf.290060403 PMID: 3191582

51. Graham JM. Isolation of nuclei and nuclear membranes from animal tissues. Curr Protoc Cell Biol. 2001; Chapter 3:Unit 3.10. Epub 2008/01/30.

52. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004; 18(8):862–76. Epub 2004/04/14. doi: 10.1101/gad.1185504 PMID: 15078817

53. Coleman ML, Densham RM, Croft DR, Olson MF. Stability of p21Waf1/Cip1 CDK inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton. Oncogene. 2006; 25(19):2708–16. Epub 2006/01/13. doi: 10.1038/sj.onc.1209322 PMID: 16407839

54. Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, et al. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci U S A. 2009; 106(23):9268–73. Epub 2009/05/28. doi: 10.1073/pnas.0805057106 PMID: 19470470

55. Rannou Y, Salaun P, Benaud C, Khan J, Dutertre S, Giet R, et al. MNK1 kinase activity is required for abscission. J Cell Sci. 2012; 125(Pt 12):2844–52. Epub 2012/03/29. doi: 10.1242/jcs.085081 PMID: 22454512

56. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004; 6(11):1122–8. Epub 2004/10/07. doi: 10.1038/ncb1183 PMID: 15467718

57. Buttrick GJ, Wakefield JG. P38-K and GSK-3: Akt-ing together with microtubules. Cell Cycle. 2008; 7(17):2621–5. Epub 2008/08/30. doi: 10.4161/cc.7.17.6514 PMID: 18728390
58. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J. Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci. 1997; 110 (Pt 3):357–68. Epub 1997/02/01.

59. Lavoie JN, Rivard N, L’Allemain G, Pouyssegur J. A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res. 1996; 2:49–58. Epub 1996/01/01. PMID: 9552382

60. Sagone AP, Stenmark H. Cytokinesis and cancer. FEBS Lett. 2010; 584(12):2652–61. Epub 2010/04/08. doi: 10.1016/j.febslet.2010.03.044 PMID: 20371245

61. Celton-Morizur S, Desdouets C. Polyploidyization of liver cells. Adv Exp Med Biol. 2010; 676:123–35. Epub 2010/08/07. PMID: 20687473

62. Sagona AP, Stenmark H. Cytokines and cancer. FEBS Lett. 2010; 584(12):2652–61. Epub 2010/04/08. doi: 10.1016/j.febslet.2010.03.044 PMID: 20371245

63. Yoshida S, Bartolini S, Pellman D. Mechanisms for concentrating Rho1 during cytokinesis. Genes Dev. 2009; 23(7):810–23. Epub 2009/04/03. doi: 10.1101/gad.1785209 PMID: 19339687

64. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003; 2(4):339–45. Epub 2003/07/10. PMID: 12851486

65. Minden A, Lin A, Clarlet FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell. 1995; 81(7):1147–57. Epub 1995/06/30. PMID: 7605852

66. Schwartz M. Rho signalling at a glance. J Cell Sci. 2004; 117(Pt 23):5457–8. Epub 2004/10/29. doi: 10.1242/jcs.01582 PMID: 15509861

67. Munsie LN, Desmond CR, Truant R. Cofilin nuclear- cytoplasmic shuttling affects cofilin-actin rod formation during stress. J Cell Sci. 2012; 125(Pt 17):3977–88. Epub 2012/05/25. doi: 10.1242/jcs.097667 PMID: 22623727

68. Pederson T. As functional nuclear actin comes into view, is it globular, filamentous, or both? J Cell Biol. 2008; 180(6):1061–4. Epub 2008/03/19. doi: 10.1083/jcb.200709082 PMID: 18347069

69. Zheng B, Han M, Bernier M, Wen JK. Nuclear actin and actin-binding proteins in the regulation of transcription and gene expression. FEBS J. 2009; 276(10):2669–85. Epub 2009/05/23. doi: 10.1111/j.1742-4658.2009.01686.x PMID: 19459931

70. Dundr M, Ospina JK, Sung MH, John S, Upender M, Ried T, et al. Actin-dependent intranuclear repositioning of an active gene locus in vivo. J Cell Biol. 2007; 179(6):1085–103. Epub 2007/12/12. doi: 10.1083/jcb.200710098 PMID: 18070915

71. Benndorf R, Hayess K, Ryazantsev S, Wieske M, Behlke J, Lutsch G. Phosphorylation and supramolecular organization of murine small heat shock protein HSP25 abolish its actin polymerization-inhibiting activity. J Biol Chem. 1994; 269(32):20763–4. Epub 1994/08/12. PMID: 8051180

72. Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, et al. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology. 2010; 51(S):1614–23. Epub 2010/03/09. doi: 10.1002/hep.23566 PMID: 20209605
80. Guo K, Liu Y, Zhou H, Dai Z, Zhang J, Sun R, et al. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase heat-shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci. 2008; 99(3):486–96. Epub 2008/01/03. doi: 10.1111/j.1349-7006.2007.00702.x PMID: 18167130

81. Dubroca C, You D, Levy BI, Loufrani L, Henrion D. Involvement of RhoA/Rho kinase pathway in myogenic tone in the rabbit facial vein. Hypertension. 2005; 45(5):974–9. Epub 2005/04/20. doi: 10.1161/01.HYP.0000164582.63421.2d PMID: 15837833

82. Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, et al. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem. 1995; 270(41):23934–6. Epub 1995/10/13. PMID: 7592586

83. Kato K, Tokuda H, Natsume H, Adachi S, Matsushima-Nishiwaki R, Minamitani C, et al. Rho-kinase regulates prostaglandin D(2)-stimulated heat shock protein 27 induction in osteoblasts. Exp Ther Med. 2010; 1(4):579–83. Epub 2010/07/01. doi: 10.3892/etm_0000091 PMID: 22993579

84. Bitar KN, Ibitayo A, Patil SB. HSP27 modulates agonist-induced association of translocated RhoA and PKC-alpha in muscle cells of the colon. J Appl Physiol (1985). 2002; 92(1):41–9. Epub 2001/12/18.

85. Patil SB, Pawar MD, Bitar KN. Phosphorylated HSP27 essential for acetylcholine-induced association of RhoA with PKCalpha. Am J Physiol Gastrointest Liver Physiol. 2004; 286(4):G635–44. Epub 2003/11/01. doi: 10.1152/ajpgi.00261.2003 PMID: 14592945

86. Bitar KN. HSP27 phosphorylation and interaction with actin-myosin in smooth muscle contraction. Am J Physiol Gastrointest Liver Physiol. 2002; 282(5):G894–903. Epub 2002/04/19. doi: 10.1152/ajpgi.00141.2001 PMID: 11960785

87. Schafer C, Ross SE, Bragado MJ, Groblewski GE, Ernst SA, Williams JA. A role for the p38 mitogen-activated protein kinase/Hsp 27 pathway in cholecystokinin-induced changes in the actin cytoskeleton in rat pancreatic acini. J Biol Chem. 1998; 273(37):24173–80. Epub 1998/09/03. PMID: 9727040

88. Chevalier D, Allen BG. Two distinct forms of MAPKAP kinase-2 in adult cardiac ventricular myocytes. Biochemistry. 2000; 39(20):6145–56. Epub 2000/05/23. PMID: 10821688

89. Kayyali US, Pennella CM, Trujillo C, Villa O, Gaestel M, Hassoun PM. Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem. 2002; 277(45):42596–602. Epub 2002/08/31. doi: 10.1074/jbc.M205863200 PMID: 12202485

90. Gurgis FM, Ziaziaris W, Munoz L. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting. Mol Pharmacol. 2014; 85(2):345–56. Epub 2013/12/04. doi: 10.1124/mol.113.090365 PMID: 24296859